多西紫杉醇联合卡培他滨治疗晚期胃癌的临床观察  

A Clinical Study on Docetaxel Combined with Capecitabine in the Treatment of Advanced Gastric Cancer

作　　者：陈火国[1] 靳文剑[1] 洪道显[1] 

机构地区：[1]江西省肿瘤医院,330029

出　　处：《实用癌症杂志》2005年第6期610-611,共2页The Practical Journal of Cancer

摘　　要：目的观察多西紫杉醇联合卡培他滨作为一线方案治疗晚期胃癌的有效性和安全性.方法46例晚期胃癌患者采用多西紫杉醇75 mg/m2静脉滴注d1;卡培他滨每日1 250 mg/m2,分2次口服,d1～14,21天为1个周期,连用2个周期后评价疗效.结果CR 4例,PR 20例,SD 15例,PD 7例,总有效率52.2%,毒副作用主要有Ⅰ～Ⅱ度恶心、呕吐、腹泻、口腔炎、手足综合征、末梢神经感觉异常及白细胞减少.结论多西紫杉醇联合卡培他滨治疗晚期胃癌疗效较高,安全性好,副作用可耐受,值得临床进一步观察.Objective To determine the efficacy and tolerability of Docetaxel combined with capecitabine as first-line treatment in advanced gastric cancer. Methods 46 patients of advanced gastric cancer were treated with Docetaxel 75 mg/m^2 ,iv gtt d1, capecitabine 1 250 mg/m^2. d, po, d 1- 14, repeated every 3 weeks （one cycle）, The effect was evaluated after two cycles. Results Complete respone in 4 pts and partial respone in 20 pts were observed with an overall response rate of 52.2% ,Adverse effects were mainly gradeⅠ - Ⅱ, including nausea and vomiting, diarrhea, stomatitis, hand-foot syndrome, neurotic and leukopenia. Conclusion Combining Docetaxel and capecitabine is an effective and better tolerated alternative treatment in advanced gastric cancer and yields promising activity.

关 键 词：晚期胃癌 多西紫杉醇 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]